Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Merck is a buy as strong cancer drug pipeline offsets Keytruda patent expiration, Morgan Stanley says

Merck, which makes the popular cancer treatment Keytruda, is poised to gain ground as its pipeline drugs get close to coming to market, per Morgan Stanley.

We haven't written up this one. CNBC has the full story — the link below goes straight to it.

This story

This is one outlet's version. Read the fullest account.

Read the original at cnbc.com →

More in Finance & Markets

More from Thursday 20 August →